An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of Ascending Doses of Lu AE04621 in Parkinson Disease Patients

NCT02649608 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson Disease

Interventions

DRUG: 0.04 mg Lu AE04621
DRUG: 0.08 mg Lu AE04621
DRUG: 0.2 mg Lu AE04621
DRUG: 0.4 mg Lu AE04621
DRUG: 0.6 mg Lu AE04621
DRUG: 0.8 mg Lu AE04621
DRUG: 1.0 mg Lu AE04621
DRUG: 1.2 mg Lu AE04621

Sponsor

H. Lundbeck A/S